Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

First-line Treatment of Locally Advanced HNSCC With Double Checkpoint Blockade and Radiotherapy Dependent on Intratumoral CD8+ T Cell Infiltration (CheckRad-CD8, EudraCT NUMBER: 2017-003226-33)

NCT03426657 is registered in ClinicalTrials.gov with University of Erlangen-Nürnberg Medical School as lead sponsor.

NCT NCT03426657
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03426657 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
First-line Treatment of Locally Advanced HNSCC With Double Checkpoint Blockade and Radiotherapy Dependent on Intratumoral CD8+ T Cell Infiltration (CheckRad-CD8, EudraCT NUMBER: 2017-003226-33)
Lead sponsor
University of Erlangen-Nürnberg Medical School
Phase
Phase 2
Overall status
Completed
Start date
September 20, 2018
Completion date
February 29, 2024
Enrollment
120 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

locally advanced head and neck squamous cell carcinoma